



REPUBLIC OF THE PHILIPPINES
OFFICE OF THE PRESIDENT

DANGEROUS DRUGS BOARD

**BOARD REGULATION NO. 4
SERIES OF 2025**

**SUBJECT: INCLUSION OF 2-FLUORODESCHLOROKETAMINE IN THE LIST OF
DANGEROUS DRUGS**

WHEREAS, the Philippines is a party to the three (3) United Nations International Drug Control Conventions: the 1961 Single Convention on Narcotic Drugs, as amended by the 1972 Protocol, the 1971 Convention on Psychotropic Substances, and the 1988 Convention Against Illicit Traffic in Narcotic Drugs and Psychotropic Substances;

WHEREAS, the Conventions aim to put in place mechanisms to address the problem of drug production, trafficking, and use of illicit substances;

WHEREAS, the Conventions provide that the Commission on Narcotic Drugs ("CND") shall have the power to change the scope of control of substances through amendment of the Schedules annexed to each Convention, and party-states shall take such measures to give effect and carry out the regulatory mechanisms provided for substances listed in the Schedules of the Conventions;

WHEREAS, 2-Fluorodeschloroketamine (IUPAC name: 2-(2-fluorophenyl)-2-(methylamino)cyclohexan-1-one) is an arylcyclohexylamine chemically related to the dissociative anesthetic ketamine and contains a chiral center, potentially existing as (R)- and (S)-enantiomers, though its enantiomeric composition on the drug market remains unclear;

WHEREAS, while 2-Fluorodeschloroketamine is not currently under international control, it is regulated under national psychoactive drug control laws in Austria, Canada, China, Germany, Italy, Latvia, Switzerland, Turkey, and the United Kingdom;

WHEREAS, available data from law enforcement seizures and user reports indicate that 2-Fluorodeschloroketamine is typically purchased in crystalline or powder form, which may be consumed through insufflation, oral ingestion, or less commonly via intramuscular, sublingual, or rectal administration;

WHEREAS, following administration, 2-Fluorodeschloroketamine undergoes extensive hepatic metabolism through N-dealkylation, oxidation, and reduction, with its primary metabolites including nor-2-fluorodeschloroketamine, dihydro-2-fluorodeschloroketamine, dihydro-nor-2-fluorodeschloroketamine, and dehydroamine-nor-2-fluorodeschloroketamine;

WHEREAS, studies on the pharmacodynamics of 2-Fluorodeschloroketamine suggest its abuse potential, with in vivo research demonstrating ketamine-like effects,

including conditioned place preference in mice, discriminative stimulus effects, locomotor sensitization in rats, and intravenous self-administration with patterns characteristic of abused drugs;

WHEREAS, the toxicology of 2-Fluorodeschloroketamine remains insufficiently studied, but its presence has been confirmed in post-mortem and impaired driving cases, with at least one fatality in Finland where it was the only detected substance and was considered highly likely to have caused the death¹;

WHEREAS, during the 67th session of the United Nations Commission on Narcotics Drug (UN-CND) held from 14 to 22 of March 2024, it was agreed that 2-Fluorodeschloroketamine be included in Schedule II of the Convention on Psychotropic Substances of 1971²;

WHEREAS, Board Regulation No.1, Series of 2020, prescribed the immediate adoption of changes in the scope of control of substances pursuant to the three (3) United Nations International Drug Control Conventions and authorized the DDB Chairperson to issue a Regulation for such purpose, provided that the DDB Chairperson and/or the DDB Executive Director shall inform the Board of the issuance of such Regulation.

WHEREFORE, be it **RESOLVED**, as it is hereby **RESOLVED**, to adopt the action of the UN-CND placing **2-Fluorodeschloroketamine** in the list of dangerous drugs and all compounds, mixtures, and preparations containing this substance, including its salts, isomers, and salts of isomers, be classified as dangerous drugs which shall be subjected to all regulatory and control measures provided for in Republic Act No. 9165, as amended, and its implementing rules and regulations.

APPROVED and **ADOPTED** this 24 day of March in the year of Our Lord, 2025, in Quezon City.


Secretary OSCAR F. VALENZUELA
Chairperson 

Attested by:


Undersecretary EARL P. SAAVEDRA, CESO I
Board Secretary / Executive Director

¹ **World Health Organization.** (2023). *Critical review report: 2-Fluorodeschloroketamine*. Expert Committee on Drug Dependence, Forty-Sixth Meeting, Geneva, 16–20 October 2023.

² **United Nations Office on Drugs and Crime.** (2024). *Resolutions and decisions (2020–2029)*. United Nations. From [https://www.unodc.org/unodc/en/commissions/CND/Resolutions Decisions/resolutions-and-decisions-2020-2029.html](https://www.unodc.org/unodc/en/commissions/CND/Resolutions%20Decisions/resolutions-and-decisions-2020-2029.html)